Clinical trial sites often open and close rapidly, with 60% ceasing operations within the first year, impacting patient ...

OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer ...

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted ...

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress ...

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.

MDX2004 is designed to activate T cells through three unique signalling pathways to enhance immune activation.

The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...

A rising wave of tumor-agnostic therapies were one of ESMO’s themes, highlighted during the opening press conference by Toni ...

The drug, JSKN003, showed promising early efficacy in colorectal cancer patients in China in a Phase I/II trial.

CITRYLL PRESENTS POSITIVE DATA FROM PHASE I STUDY OF CIT-013 IN RHEUMATOID ARTHRITIS AT ACR CONVERGENCE 2025. Phase I trial data in rheumatoid arthritis patients demonstrates favo ...

CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts Next-generation Hydrocortisone Acetate (ngHCA™) Suppository Administered with Sephure® Suppos ...